Masimo Becomes First Pulse Oximetry
Manufacturer to be Recognized with Coveted “Greenhealth Approved”
Seal
Masimo (NASDAQ: MASI), a leading medical technology innovator,
and Practice Greenhealth, a prominent organization dedicated to
advancing sustainability solutions for healthcare providers, today
announced that Masimo is now a recipient of the Greenhealth
Approved seal. Masimo’s products – in particular its line of RD
pulse oximetry sensors – are the first pulse oximetry products to
receive the Greenhealth sustainability seal. The seal is only
granted to products that meet specific sustainability criteria,
making it a reliable indicator for health care providers seeking to
identify environmentally preferable products without the time and
expense needed to conduct their own independent verification.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240520445594/en/
Greenhealth Approved: Masimo RD Pulse
Oximetry Sensors (Graphic: Business Wire)
Bilal Muhsin, Chief Operating Officer, Masimo, said, “Masimo is
committed to both excellent patient care and environmental
responsibility. The RD pulse oximetry sensor line was designed with
the environment in mind, so we are pleased and proud to be the
first to receive the Greenhealth Approved seal in this
category.”
Masimo continually strives to make its products, packaging, and
facilities more environmentally friendly and has implemented a
variety of green initiatives, including designing products that
promote sustainability by eliminating unnecessary material from
being introduced into the product stream, expansion of its sensor
recycling program, which is committed to achieving “zero waste to
landfill,” and partnership with sustainability-focused
organizations such as Practice Greenhealth.
From sensor design to disposal, Masimo uses materials that are
less wasteful without compromising quality or performance. In
addition to meeting the chemicals criteria of Health Care Without
Harm, RD single-patient-use pulse oximetry sensors also:
- Reduce waste by 84% when compared to cable-based sensors1
- Achieve zero waste to landfill through Masimo’s sensor
recycling program
- Allow for “reprocessing at the bedside” with replacement
tapes
- Offer best-in-class SpO2 accuracy specifications of 1.5% ARMS*
and accurately measure on patients with varying skin pigmentation
and low perfusion2,3
- Maximize patient comfort with low-profile, lightweight
components
- Use the same, standardized connector for multiple sensor
technologies (e.g. SET® and rainbow®)
The review process for the Greenhealth Approved seal includes
the submission of a complete ingredient list along with proof of
certifications for the category’s criteria. “Greenhealth Approved
removes obstacles that previously made purchasing sustainable
products difficult,” said Paul Bogart, Executive Director of
Practice Greenhealth. “Normally each health care provider conducts
its own product review, often without extensive experience in
chemistry and sustainability. We are helping streamline and
centralize this approach, working closely with each supplier and
completing a detailed product review using trusted criteria.
Greenhealth Approved allows health care providers to quickly and
easily identify and purchase sustainable products that decrease
their impact on the environment.”
Providers interested in finding out which products carry the
Greenhealth Approved seal can check the website and sign up for
regular updates as products are approved for the seal. Practice
Greenhealth is the leading sustainable health care organization,
delivering environmental solutions to more than 1,700 hospitals and
health systems in the United States and Canada.
Masimo will be exhibiting its Greenhealth-approved RD pulse
oximetry sensors at CleanMed 2024, the premier health care
sustainability conference, hosted by Practice Greenhealth and
Health Care Without Harm, on May 21st - 23rd in Salt Lake City,
Utah.
@Masimo | #Masimo
* ARMS accuracy is a statistical calculation of the difference
between device measurements and reference measurements.
Approximately two-thirds of the device measurements fell within ±
ARMS of the reference measurements in a controlled study.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.4
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,5 improve CCHD screening in
newborns6 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.7-10 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,11 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.12 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97® and the
Masimo W1® medical watch. Masimo hospital and home automation and
connectivity solutions are centered around the Masimo Hospital
Automation™ platform, and include Iris® Gateway, iSirona™, Patient
SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo
SafetyNet®. Its growing portfolio of health and wellness solutions
includes Radius Tº®, Masimo W1 Sport, and Masimo Stork™. Additional
information about Masimo and its products may be found at
www.masimo.com. Published clinical studies on Masimo products can
be found at www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Internal data on file.
- Barker SJ, Wilson WC. J Clin Monit Comput.
2023;37:567-574.
- Sharma, et al. J Clin Monit Comput. 2024 Jan;38:347-354.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
About Practice Greenhealth
Practice Greenhealth is the leading sustainable health care
organization, delivering environmental solutions to more than 1,700
hospitals and health systems in the United States and Canada.
Partnership opportunities include NGOs, nonprofits, government,
academic institutions, and the health care value chain.
Practice Greenhealth is the innovation hub scaling the work of
Health Care Without Harm, an organization that seeks to transform
health care worldwide. For more information, visit
practicegreenhealth.org.
Forward-Looking Statements - Masimo
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo RD pulse oximetry
sensors and the benefits for them to be Greenhealth Approved. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo RD pulse oximetry sensors,
contribute to positive clinical outcomes and patient safety; risks
that Masimo fails to exhibit its Greenhealth-approved RD pulse
oximetry sensors at CleanMed 2024; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions and unique advantages; risks related to COVID-19; as well
as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange
Commission ("SEC"), which may be obtained for free at the SEC's
website at www.sec.gov. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All
forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today's date. We
do not undertake any obligation to update, amend or clarify these
statements or the "Risk Factors" contained in our most recent
reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240520445594/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Practice Greenhealth Ella Schwotzer 866-310-3320
press@practicegreenhealth.org
Masimo (NASDAQ:MASI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024